ACTR-20. A SMALL MOLECULE AXL INHIBITOR, BGB324 – FIRST-IN-HUMAN GBM SURGICAL PK TRIAL FOR RECURRENT TUMORS

Glioblastoma (GBM) remains the deadliest of all primary brain tumors with very few effective treatment options. Recently, we reported that high AXL expression is correlated with poor prognosis in GBM patients and demonstrated the therapeutic benefits of targeting AXL, a member of TAM receptor tyrosi...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Ghosh, Sadashib, Sadahiro, Hirokazu, Kang, Kyung-Don, Gibson, Justin T, Minata, Mutsuko, Yu, Hai, Shi, Junfeng, Chhipa, Rishi, Chen, Zhihong, Lu, Songjian, Simoni, Yannick, Furuta, Takuya, Sabit, Hemragul, Zhang, Suojun, Bastola, Soniya, Yamaguchi, Shinobu, Alsheikh, Heba Allah, Komarova, Svetlana, Wang, Jun, Kim, Sung-Hak, Hambardzumyan, Dolores, Lu, Xinghua, Newell, Evan W, Dasgupta, Biplab, Nakada, Mitsutoshi, Lee, L James, Nabors, L Burt, A. Norian, Lyse, Nakano, Ichiro
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2018
主題:
Abstracts
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216174/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.054
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料